Arena Pharmaceuticals, Inc.

NASDAQ: ARNA
$81.34
+$0.99 (+1.2%)
Closing price October 23, 2020
Ahead of the California legalization efforts, a U.S.-listed marijuana-focused exchange traded fund has quietly begun trading.
Shares of Arena Pharmaceuticals saw an incredible gain early Tuesday after the company reported positive results from its mid-stage trial in patients with pulmonary arterial hypertension.
The top analyst upgrades, downgrades and other research calls from Tuesday include Alibaba, BHP Billiton, Cintas, Monsanto, Schlumberger, Shopify, Hess and Western Digital.
The top analyst upgrades, downgrades and other research calls include Alphabet, Enterprise Products, GrubHub, Mattel, Ryanair and Splunk.
The the man in charge of one of the nation's biggest railroads was among insiders making notable purchases of shares this past week.
Valeant, Arena, Teva, and Frontier Communications all posted new 52-week lows on Tuesday.
Arena Pharmaceuticals saw its shares drop sharply on Tuesday after the company announced a secondary offering of 60 million shares of its common stock.
The broad markets are inching forward on Wednesday after hitting new highs in what has been known as the Trump rally. Although the SPDR S&P Biotech ETF (NYSEMKT: XBI) is up about 1% on the day,...
The impact of cannabis products is expected to grow to an estimated $44 billion by 2020. Which companies will be earning those billions?
These biotech companies stood out from the rest with incredible gains or losses over the course of the past week.
Arena Pharmaceuticals saw its shares jump in Monday’s session on news of an U.S. Food and Drug Administration (FDA) approval.
A new research note from the quantitative strategies team at Jefferies highlights the top buys and sells for the Russell 1000 and Russell 2000. These five companies will see the most shares bought on...
Credit Suisse has launched new biotech coverage on Wednesday with two analysts at the firm.
Source: ThinkstockVIVUS Inc. (NASDAQ: VVUS) investors have a lot to be disappointed about these days. America’s ballooning waistline is reaching a critical level, yet VIVUS did not even manage to...
24/7 Wall St. ran a screen of the Wall Street firms we cover looking for biotech stocks trading under $10 that had big upside potential for 2014. These are potentially the next great growth engines...